2019 Investments Centered around Cell and Gene Therapies

Previous investments set a foundation for later efficiency improvements.

In 2019, cold-chain service providers continued investments in platforms and services designed for gene and cell therapy clinical studies. Marken acquired a logistics firm in Japan, and expanded logistics operations in Philadelphia with a new GMP-compliant plant and liquid nitrogen storage facilities, says president Ariette Van Strien.

Read more on this article by clicking here.